US Earnings Financial Results SEC Filings — March 30, 2026

30-03-2026

OneMedNet Corp reported total revenue of $1,359 thousand for the year ended December 31, 2025, up 111% YoY from $643 thousand, driven by a 329% surge in data delivery revenue (Real-World Data) to $1,254 thousand; however, subscription revenue (BEAM) declined sharply 70% to $105 thousand. The net loss narrowed 72% to $2,801 thousand from $10,129 thousand, benefiting from $5,569 thousand gain on troubled debt restructurings and other non-operating income, though gross margins remained negative at $(503) thousand (worsened 79% YoY) and the company faces going concern doubts amid bitcoin holdings risks. Target markets include Imaging AI, medical device companies, and pharmaceutical companies, with the Real World Evidence market projected to grow from $2.62B in 2024 to $4.55B by 2030 at 8.2% CAGR.

• ·Cost of revenue increased to $1,862 thousand (137% of revenue) from $924 thousand (144% of revenue).
• ·Company highlights risks including going concern, revenue decline reversal, IP protection, bitcoin volatility, and third-party supplier reliance.
• ·Long-term strategies focus on global reach expansion and sales network growth targeting Imaging AI, medical device, and pharmaceutical companies.

30-03-2026

Perimeter Acquisition Corp. I (PMTRW), a blank check company with no operating history or revenues, filed its 10-K on March 30, 2026, disclosing sponsor compensation including 5,911,500 founder shares for $24,460 and 638,000 private placement units, alongside up to $1,500,000 in convertible working capital loans at $10.00 per unit that could cause significant dilution. The filing details 180-day transfer restrictions on founder shares post-IPO or business combination, uncapped reimbursement for sponsor out-of-pocket expenses, and redemption mechanics at approximately $10.00 per share in case of business combination or failure within 24 months of IPO closing. No initial business combination has been completed.

• ·Transfer restrictions on founder shares apply until 180 days after initial business combination or subsequent liquidation/merger/share exchange.
• ·Must complete initial business combination within 24 months from IPO closing or redeem public shares.
• ·No cap on reimbursement of out-of-pocket expenses for sponsor, officers, directors, or affiliates related to business combination activities.
• ·Private placement warrants are non-redeemable.

30-03-2026

AIxCrypto Holdings reported total assets of $31,279,846 as of December 31, 2025, up significantly from $4,686,519 in 2024, driven by cash and cash equivalents rising to $19,332,707 and new digital assets of $10,250,497, bolstered by $40,991,044 in financing activities including $4.5 million from Series A-3 Preferred and substantial Series B Preferred issuances. However, the company posted a larger net loss attributable to shareholders of $19,528,742 in 2025 versus $6,346,795 in 2024, with total expenses increasing 129% to $13,202,096 due to higher general and administrative costs and a $4,195,000 credit loss expense, alongside a $3,588,106 net loss on digital assets. Stockholders’ equity grew to $27,950,609 from $2,679,036, but operating cash use worsened slightly to $(6,951,458).

• ·Short-term notes receivable net: $343,060 (2025) vs $2,010,692 (2024), after allowance of $4.6M (2025) vs $360,000 (2024).
• ·Related party payable: $1,648,945 (2025) vs $0 (2024).
• ·Issuance of $4,166,900 notes receivable to a publicly traded entity from Apr 2024-Dec 2025 at 18% interest.
• ·Secured Convertible Note $264,000 principal (+$44,000 OID) issued Apr 2025, repaid Jan 2026.
• ·Subscription agreement Sept 19, 2025 for $41M: issued 337,432 common shares and 17,783 Series B shares by Sept 29, 2025.

30-03-2026

Greenpro Capital Corp. (GRNQ) outlines its core services in its 10-K filing, including advising on company formation in jurisdictions like Hong Kong, the US, and British Virgin Islands, corporate finance consulting, FinTech solutions such as cloud accounting and payroll systems, cross-border listing advisory, and digital asset services like cryptocurrency trading and equity crowdfunding for SMEs. The company supports client financing stages from seed to expansion to enable global business development and increased cash flows. However, it highlights substantial risks including digital asset price volatility, regulatory scrutiny, banking service restrictions, market manipulation, concentrated ownership, and potential non-compliance penalties in China that could harm operations.

• ·Filing Date: March 30, 2026
• ·Services include bank loan referrals, company secretarial services, due diligence investigations, liquidation and insolvency advice, international tax planning in China, and trust/wealth management advisory
• ·Client financing stages: Seed (assets/R&D), Start-up (product development/initial marketing), Expansion (growth/production capacity)
• ·Risks encompass blockchain partnership failures, limited digital asset acceptance by retailers/banks, lack of liquid markets, whale sales impact, system outages, cyberattacks, and China regulatory penalties like fines, injunctions, or license losses

30-03-2026

Akari Therapeutics' total operating expenses declined 20% YoY to $17,275 thousand for the year ended December 31, 2025, from $21,643 thousand in 2024, driven by a sharp 60% drop in R&D expenses to $2,815 thousand and elimination of one-time merger-related ($3,273 thousand) and restructuring expenses ($1,723 thousand). However, G&A expenses were nearly flat, down only 4% to $9,280 thousand, and the company recorded a new $5,180 thousand impairment loss on other intangible assets, resulting in an operating loss of $17,275 thousand. The filing highlights ongoing operating losses, material weaknesses in internal controls, no initiated clinical studies, and the need for substantial additional capital amid various development and regulatory risks.

• ·Identified material weaknesses in internal control over financial reporting.
• ·No clinical studies initiated for any programs in active pipeline.
• ·Entered White Lion Ordinary Share Purchase and Registration Rights Agreements with purchase options at 97-100% of ADS prices or with 20% discount under certain conditions.
• ·Risk of Nasdaq delisting due to past and potential future non-compliance.
• ·Relies on novel, unproven ADC Platform technologies.

30-03-2026

For the year ended December 31, 2025, ImmuCell Corp reported product sales growth of 4% YoY to $27,644,174, driven by a 13% decline in costs of goods sold, resulting in gross profit surging 44% to $11,445,203 and net operating income turning positive at $1,649,305 from a prior loss. However, administrative expenses increased 44%, other expenses net rose 429% to $2,677,762, and a $2,667,100 impairment charge on property, plant, and equipment was recognized after pausing investment in Re-Tain® manufacturing to focus on First Defense®, contributing to a narrowed net loss of $1,040,027 (52% improvement) while total assets declined 6% to $42,532,447.

• ·Net cash provided by operating activities increased to $2,475,292 in 2025 from $357,903 in 2024.
• ·Net cash used for investing activities was $1,214,307 in 2025 vs $461,225 in 2024.
• ·Inventory increased to $9,267,369 as of Dec 31 2025 from $7,112,623.
• ·Property, plant and equipment net decreased to $21,074,694 as of Dec 31 2025 from $25,349,019.
• ·Critical audit matters include valuation of inventory and impairment of PPE related to Re-Tain® assets.
• ·Leased properties total approx. 29,700 sq ft (175A and 175B Industrial Way) for milling, filling, warehouse.

30-03-2026

General Enterprise Ventures, Inc. reported revenue of $2,381,407 for the year ended December 31, 2025, marking a 195% increase from $808,372 in 2024. However, operating expenses surged 209% to $18,877,398, other expenses skyrocketed 1,190% to $20,341,652, and the net loss widened dramatically by 435% to $36,837,643 from $6,881,722. The company highlighted ongoing risks including high leverage, stock volatility, dilution from share issuances, and challenges in achieving profitability.

• ·Recent sales of unregistered securities included 220,000 shares for IP acquisition valued at $1,775,400 from Breakthrough Chemistry, Inc.
• ·346,127 shares issued via cashless conversion of 359,375 warrants.
• ·500,000 shares issued upon conversion of 150,000 shares of Series C Convertible Preferred Stock.
• ·475,862 shares issued for conversion of $1,071,821 in debt and accrued interest.
• ·55,333 shares issued for services valued at $443,377.

30-03-2026

Picard Medical, Inc. reported total net revenues of $4,940 thousand for the year ended December 31, 2025, up 13% YoY from $4,391 thousand, with products revenue increasing 12% to $4,746 thousand and rentals surging 42% to $194 thousand. However, gross loss widened 82% to $(204) thousand due to a 38% rise in product costs to $3,432 thousand despite a 15% decline in rental costs, while net loss grew 28% to $(27,002) thousand driven by 86% higher other expenses including derivative losses up 64% and interest expense up 76%. Operating expenses declined slightly 4% to $13,053 thousand with R&D down 10% and SG&A flat at -2%, and cash balances improved to $7,451 thousand from $96 thousand bolstered by financing activities.

• ·Auditors included explanatory paragraph on going concern due to ability to continue as a going concern.
• ·Cash used in operating activities increased to $15,673 thousand from $11,874 thousand.
• ·No cash used in investing activities in either year.
• ·Total current liabilities decreased to $18,695 thousand from $35,325 thousand.
• ·Preferred stock converted to common stock; no Series A-1 outstanding as of Dec 31 2025.
• ·Stock-based compensation expense $754 thousand in 2025.

30-03-2026

HyOrc Corp's 10-K filing discloses a retained earnings deficit of $8,174,862, impairment loss of $300,000, credit loss of $95,747, and net cash used in operating activities of $336,057, reflecting ongoing cash burn and no revenue from its key joint venture. The company is developing an 8 TPD waste-to-methanol pilot facility in Portugal with Start Lda, not yet operational and expected no earlier than July 2026, with plans to expand to 80 TPD subject to financing and risks. Market capitalization stands at $62.3 million based on 737 million outstanding shares trading at $0.0845 per share, with no dividends expected.

• ·Phase 1 pilot facility not operational until July 2026 or later due to permitting, equipment, financing risks
• ·No binding off-take agreements in place for the project
• ·Company not generating revenue under Joint Venture Agreement with Start Lda
• ·No dividends paid historically and none expected
• ·Common stock quoted on OTCQB under ticker HYOR

30-03-2026

Soluna Holdings reported total revenue of $29,717 thousand in 2025, down from $38,021 thousand in 2024, driven by a 33% decline in cryptocurrency mining revenue to $11,406 thousand and a 10% drop in data hosting revenue to $16,998 thousand, though high-performance computing service revenue rose 75% to $28 thousand. Operating loss improved 29% to $(33,681) thousand and net loss attributable to Soluna narrowed 16% to $(53,411) thousand, but adjusted EBITDA turned negative at $(13,229) thousand from $942 thousand. Cash balance surged to $76,423 thousand from $7,843 thousand, bolstered by $119,392 thousand in net financing cash flows.

• ·General and administrative expenses excl. dep. & amort. increased 64% to $30,519 thousand.
• ·Interest expense rose 91% to $4,835 thousand.
• ·Gross profit for Soluna Digital was $6,437 thousand across projects.
• ·Net cash used in operating activities was $9,149 thousand.
• ·Purchase of property, plant and equipment was $31,719 thousand.

30-03-2026

Origin Materials reported total revenues of $18,922 thousand for 2025, down 40% YoY from $31,282 thousand, primarily due to lower product sales, while services revenue dropped to zero from $3 thousand. A massive $195,636 thousand asset impairment drove operating expenses up 204% to $259,634 thousand and net loss to $(249,698) thousand, worsening 198% from $(83,697) thousand; however, Adjusted EBITDA improved to $(43,368) thousand from $(48,367) thousand, and net cash used in operations decreased to $(32,793) thousand from $(50,830) thousand. Total assets shrank to $157,660 thousand from $378,027 thousand, with cash and equivalents at $32,923 thousand.

• ·Stock-based compensation decreased to $8,914 thousand from $10,080 thousand.
• ·Net cash provided by financing activities increased to $10,659 thousand, driven by $15,000 thousand proceeds from convertible notes.
• ·Common stock warrants liability decreased to $167 thousand from $4,566 thousand.

30-03-2026

Aldabra 4 Liquidity Opportunity Vehicle, Inc. (ALOV), a blank check company incepted on July 24, 2025, reported total assets of $285,064, including $23,583 in cash and $261,481 in deferred offering costs, as of December 31, 2025. Total liabilities stood at $338,146, resulting in a shareholder’s deficit of $53,082, with a net loss of $78,082 for the period from inception through December 31, 2025, driven entirely by formation and general administrative expenses and no revenue.

• ·Accounts payable: $11,246 as of December 31, 2025
• ·Accrued expenses: $13,125 as of December 31, 2025
• ·Accrued offering costs: $113,775 as of December 31, 2025
• ·Basic and diluted net loss per Class B ordinary share: ($0.01)
• ·Class B ordinary shares authorized: 20,000,000

30-03-2026

JENA ACQUISITION Corp II, a blank check company with no operating history or revenues, reported total assets of $236,574,719 as of December 31, 2025, driven by $235,449,992 in the Trust Account from 23,000,000 Class A Ordinary Shares at $10.24 per share. For the period from inception (February 24, 2025) to December 31, 2025, it recorded a net loss of $1,836,775 on a $7,286,767 operating loss from formation costs ($386,767) and advisory fees ($6,900,000), partially offset by $5,449,992 in Trust Account interest income, resulting in a shareholders' deficit of $12,700,299. No business combination has been completed, limiting evaluation of future prospects.

• ·Basic and diluted net loss per share of $0.08 for both Class A and Class B Ordinary Shares.
• ·Risks include potential negative interest rates on Trust Account investments, post-combination foreign asset/revenue concentration, and limited shareholder basis for evaluation due to no revenues or operations.

30-03-2026

Remora Capital Corp's 10-K annual report filing highlights its pursuit of regulated investment company (RIC) status under subchapter M of the Internal Revenue Code and business development company (BDC) status under the 1940 Act, including asset composition requirements such as at least 50% in cash equivalents and limited issuer exposures. It references small company thresholds of total assets not exceeding $4 million and capital/surplus of at least $2 million, alongside a gross revenue trigger of $1.235 billion. Risks disclosed include corporate debt market declines reducing portfolio NAV, global economic uncertainties affecting operations, and mandatory debt prepayments limiting portfolio company flexibility.

• ·RIC asset test limits: other securities of any one issuer not more than 5% of assets or 10% of voting securities.
• ·Risk of increased net unrealized depreciation from price declines and illiquidity in corporate debt markets.

30-03-2026

HCM III Acquisition Corp., a SPAC, reported net income of $2,192,991 for the period from inception (April 15, 2025) through December 31, 2025, driven by $4,298,929 in interest from the Trust Account holding $257,298,929 (25,300,000 Class A shares at $10.17 redemption value). However, the company raised substantial doubt about its ability to continue as a going concern due to only $1,015,282 in cash, operating losses of $914,236, and a shareholders' deficit of $12,787,848, potentially requiring additional funding from its Sponsor amid risks of liquidation if no business combination is completed.

• ·Basic and diluted net income per ordinary share: $0.10 for both Class A and Class B shares.
• ·Over-allotment option exercised in full by underwriters on August 4, 2025.
• ·Net cash used in operating activities: $355,263.
• ·Non-cash deferred underwriting fee payable: $12,045,000.

30-03-2026

Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported in its 10-K that it has never generated product revenues, anticipates significant ongoing losses, and has substantial doubt about its ability to continue as a going concern due to the need for substantial additional capital. The company is heavily dependent on brilaroxazine, its sole advanced product candidate still in clinical development, with no offsetting positive financial metrics or achievements noted. Risks include material weaknesses in internal controls over financial reporting as of December 31, 2025, potential Nasdaq delisting, reliance on third parties for trials and manufacturing, and significant competition.

• ·Certain warrants are accounted for as liabilities, with changes in value potentially having a material effect on financial results.
• ·No current intention to pay dividends on common stock in the foreseeable future.

30-03-2026

HCM IV Acquisition Corp., a blank check company and shell entity, reported total assets of $160,959, primarily consisting of $25,000 in prepaid expenses and $135,959 in deferred offering costs as of December 31, 2025. The company recorded a net loss of $59,655 from formation and administrative costs for the period from inception (September 5, 2025) through December 31, 2025, resulting in total liabilities of $195,614 (including a $154,819 related party promissory note) and a shareholders' deficit of $34,655, with zero cash on hand at period end.

• ·Entity is a shell company (true), emerging growth company (true), small business (true), and non-accelerated filer.
• ·Entity Central Index Key: 0002089982; Entity Tax ID: 98-1883478.
• ·Address: 85 Washington St, 1F, Stamford, CT 06854; Phone: (203) 930-2200.
• ·Securities listed on NASDAQ.
• ·Basic and diluted net loss per Class B share: $(0.01).
• ·Net cash used in operating activities: $0.

30-03-2026

Cottonwood Communities, Inc. (CROP) reported NAV of $1,013,012 as of December 31, 2025, reflecting a decline in NAV per share to $11.3574 from $12.0083 at year-end 2024 (-5.4% YoY), though a valuation guideline change added approximately $19.42 million ($0.32 per share). Total revenues fell 2.9% YoY to $153,934 from $158,483, with rental revenues down 4.8% to $138,787, but Core FFO rose sharply 266% to $15,932 from $4,348, and net loss attributable to controlling interests improved to $(4,844) from $(10,956). The company repurchased 1,374,067 shares in Q4 2025 at an average price of about $11.29 per share.

• ·FFO per common share and unit - diluted: $(0.23) in 2025 vs $(0.01) in 2024.
• ·Core FFO per common share and unit - diluted: $0.22 in 2025 (up from $0.07).
• ·Stockholders’ equity: 282,807 as of Dec 31, 2025.
• ·Weighted-average diluted common shares and units: 71,259,649 in 2025 (up from 66,472,501).

30-03-2026

Gores Holdings X, Inc., a SPAC, completed its IPO in 2025, raising $358,800,000 in proceeds and funding the Trust Account to $367,742,183, with net income of $920,659 driven by $9,511,647 in interest income. However, the company reported an operational net loss of $1,850,155, a $6,637,800 expense from change in fair value of public warrant liabilities, and basic/diluted net loss per share of $(0.76) across all classes due to accretion of temporary equity, resulting in shareholders' deficit widening to $(31,301,532) from $(40,000). Total assets grew significantly to $368,717,492 from $1,184,632, while cash ended at $619,576.

• ·IPO underwriter's discounts and commissions payment: $250,000
• ·Public warrants derivative liability: $8,162,700 as of Dec 31, 2025
• ·Initial classification of warrant liability - public (non-cash): $1,524,900
• ·Notes payable - related party repaid: $231,901 (after $59,000 proceeds)

30-03-2026

The 21Shares Solana ETF (TSOL), launched on September 17, 2025, reported net assets of $5,735,019 as of December 31, 2025, with 460,000 shares outstanding at a NAV of $12.47 per share, down from higher inflows amid Solana holdings valued at $5,770,226 (cost basis $6,518,230). It generated $203,951 in staking fee income and $176,055 net investment income, but suffered a net realized and unrealized loss of $4,323,701, primarily from $3,578,079 realized loss on Solana sales and $748,004 unrealized depreciation, leading to a $4,147,646 net decrease from operations. Gross contributions totaled $119,956,526 while redemptions were $110,073,861, reflecting high turnover.

• ·Paid-in-capital: $9,882,665
• ·Staking fee payable: $19,187; Sponsor fee payable: $8,334; Block rewards payable: $7,686
• ·Solana purchased: 852,012.1255 quantity for $119,952,208
• ·Solana sold for redemptions: (807,060.9488) quantity for ($110,069,543)

30-03-2026

RG&E Storm Funding, LLC, a bankruptcy-remote subsidiary of Rochester Gas and Electric Corporation, filed its annual 10-K for the fiscal year ended December 31, 2025, omitting most sections per General Instruction J for asset-backed securities issuers. The filing confirms no material instances of noncompliance with servicing criteria by the servicer (Rochester Gas and Electric Corporation) or indenture trustee (U.S. Bank Trust Company, National Association). It discloses ongoing litigations involving U.S. Bank as trustee in unrelated RMBS and student loan trusts, though U.S. Bank denies liability and asserts meritorious defenses.

• ·Managers and executive officers listed as of March 27, 2026: Michael Panichi (age 39), Andrea VanLuling (age 43), Michelle A. Dreyer (age 53).
• ·Key agreements dated February 14, 2025: Indenture, Series Supplement, Recovery Property Servicing Agreement, Recovery Property Purchase and Sale Agreement, Administrative Agreement.
• ·Auditor: KPMG, LLP (Firm ID: 185), New York, New York.
• ·Litigation details: U.S. Bank involved in RMBS trustee lawsuits and NCMSLT Action (C.A. No. 2018-0167-JRS, Del. Ch.), stayed and consolidated as of January 21, 2020.

30-03-2026

CIM Real Estate Finance Trust's total investment portfolio slightly declined 1.6% YoY to $4,686,426 across 294 assets from $4,764,899 across 276 assets, with loans held-for-investment net increasing to $3,454,589 (73.8%) but real estate-related securities net dropping sharply to $169,206 (3.5%) from $345,828 (7.3%). The company achieved a significant turnaround to net income attributable to the Company of $52,356 from a loss of $292,301, supported by lower expenses and real estate NOI growth of 13.9% to $98,940, though total revenues fell 14.0% to $416,004 and distributions decreased to $152,510 from $196,675.

• ·Credit segment revenues declined $85,667 YoY to $304,321.
• ·Current expected credit losses on loans improved to $(297,878) from $(392,136).
• ·Unused borrowing capacity decreased to $52,776 from $91,786.
• ·Weighted-average interest rate for CRE loans: 7.0%; Corporate senior loans: 9.5%.
• ·Same store rental income grew minimally by $421 to $86,333.

30-03-2026

CISO Global serves more than 437 clients across diverse sectors, with penetration of only approximately 20% for multiple services, positioning the company for revenue growth through cross-selling and upselling. However, it incurred significant operating losses during the years ended December 31, 2025 and 2024, has limited cash flow, and faces substantial doubt about its ability to continue as a going concern, with the auditor's opinion including an explanatory paragraph on this matter. The filing highlights strategic strengths like proprietary software and partnerships alongside extensive risk factors including talent shortages, long sales cycles, and competitive pressures.

• ·Dependence on a significant customer for a material portion of revenue and accounts receivable.
• ·Expectation not to pay cash dividends in the foreseeable future.
• ·Industry shortage of qualified compliance and cybersecurity professionals.
• ·Long and unpredictable sales cycles.
• ·Auditor’s opinion on financial statements for year ended December 31, 2025, includes going concern explanatory paragraph.

30-03-2026

Carlyle Private Equity Partners Fund, L.P. (CPEP) reported total net assets of $46,182 and total assets of $59,046 as of December 31, 2025, for the period from inception on February 11, 2025, driven by $46,997 in proceeds from unit issuances. Investments at fair value totaled $44,900 (cost basis $41,722), representing 97.22% of net assets, with cash and cash equivalents at $11,176; however, there was a net decrease in net assets resulting from operations of $(740). Net cash used in operating activities was $(35,820), offset by strong financing inflows.

• ·Cost of investments purchased: $42,076; Proceeds from sales and repayments: $408
• ·Net realized gain on investments: $(55); Net change in unrealized appreciation on investments: $(3,177)
• ·Equity securities purchases: $33,823; Net change in unrealized appreciation on equity securities still held: $2,139
• ·Level III valuation: Discount rate weighted average 12.19% (range 8.20%-16.78%), Terminal growth rate 4.28% (2.00%-11.00%)
• ·Total investments cost breakdown: $29,034 Americas, $9,095 Europe, $3,478 Australia, $7,850 Japan, $3,098 Other Asia

30-03-2026

Vine Hill Capital Investment Corp. II (VHCP), a SPAC, filed its 10-K annual report on March 30, 2026, including audited financial statements for the period from inception on August 18, 2025, to December 31, 2025. The filing outlines strategies for transforming target businesses post-business combination to accelerate revenue growth and improve margins, while highlighting risks such as substantial debt service reducing cash available for dividends and operations, limitations on borrowing, and potential change of control from share issuances exceeding 60% of equity proceeds.

• ·Financial statements cover period from August 18, 2025 (inception) to December 31, 2025
• ·Includes Balance Sheet as of December 31, 2025; Statement of Operations; Statement of Changes in Shareholders’ Deficit; Statement of Cash Flows
• ·Risk of change of control if substantial ordinary shares issued

30-03-2026

NYSEG Storm Funding, LLC, a wholly-owned bankruptcy-remote subsidiary of New York State Electric & Gas Corporation (itself a subsidiary of Avangrid, Inc.), filed its Form 10-K for the fiscal year ended December 31, 2025, with most content omitted per General Instruction J for asset-backed issuers. The filing confirms no material instances of noncompliance with servicing criteria by servicer New York State Electric & Gas Corporation or trustee U.S. Bank National Association. It discloses ongoing litigations against the trustee in RMBS and student loan trusts (with liability denied) and lists managers including Michael Panichi as President and Treasurer.

• ·Managers and officers listed as of March 27, 2026.
• ·Key agreements dated February 11, 2025: Indenture, Series Supplement, Recovery Property Servicing Agreement, Recovery Property Purchase and Sale Agreement, Administrative Agreement.
• ·Audited by KPMG, LLP (Firm ID: 185).
• ·Ongoing RMBS trustee litigations and NCMSLT Action (Del. Ch. C.A. No. 2018-0167-JRS) against U.S. Bank disclosed, with motions to dismiss/stay and consolidation orders noted; U.S. Bank denies liability.

30-03-2026

GBank Financial Holdings Inc. reported net income of $20.9 million for the year ended December 31, 2025, up 12% from $18.6 million in 2024, with diluted EPS increasing to $1.44 from $1.39 and loan growth of $143.3 million or 18% YoY. However, profitability metrics declined with return on average assets falling to 1.70% from 1.85%, return on average equity dropping to 13.61% from 16.14%, and net interest margin compressing to 4.33% from 4.79%, while non-performing assets rose sharply to $37.4 million or 2.75% of total assets from $14.2 million or 1.26%. Noninterest income surged 56.2% to $25.3 million driven by net interchange fees up 477% and loan servicing up 81%, but noninterest expenses increased 24.4% to $45.1 million.

• ·Average earning assets increased to $1,171.8 million in 2025 from $963.9 million in 2024.
• ·Total interest-bearing deposits grew to $806.1 million average in 2025 from $622.6 million in 2024.
• ·Guaranteed loans totaled $229.7 million as of Dec 31, 2025, slightly down from $233.9 million as of Dec 31, 2024.
• ·Net interest income rose $4.5 million or 9.8% to $50.7 million in 2025.

30-03-2026

Hyperion DeFi, Inc. reported revenue of $813,455 for FY 2025, up significantly from $57,336 in FY 2024, with gross profit turning positive at $510,165 from a $3,869,892 loss; net loss narrowed to $45,314,435 from $49,818,433. However, the company recorded massive impairments and unrealized losses on digital assets totaling over $36 million, alongside elevated SG&A expenses of $17,175,698 (up from $14,333,114), while R&D expenses dropped sharply to $1,910,430 from $14,462,722. Liquidity improved markedly with cash rising to $6,443,467 from $2,121,463 and working capital turning positive at $4,544,796 from a $13,279,008 deficit.

• ·Notes Payable (Gross) decreased to $8,339,366 as of Dec 31, 2025 from $10,740,402 as of Dec 31, 2024.
• ·Total Stockholders’ Equity turned positive at $41,060,507 as of Dec 31, 2025 from a deficit of $(13,095,952) as of Dec 31, 2024.
• ·Net Loss per Share improved to $(9.40) from $(59.81), with weighted average shares outstanding at 5,000,331 vs 832,997.

30-03-2026

For the year ended December 31, 2025, American Picture House Corp (APHP) reported revenues of $853,017, a 1,521% YoY increase from $52,677, driven by film-related activities including a $1,150,000 receivable from Barron’s Cove, resulting in a reduced net loss of $(534,440) from $(2,270,258) in 2024. Operating expenses declined 38% to $1,413,586, primarily due to lower general and administrative costs, while total assets grew 28% to $1,505,916. However, the company remains unprofitable with liabilities exceeding assets ($1,763,463 vs. $1,505,916), widening the stockholders' equity deficit to $(257,547), and cash balances critically low at $124.

• ·APHP entitled to $1,150,000 first-priority from Barron’s Cove net revenues waterfall, plus 15% split until recoupment.
• ·Cash and cash equivalents: $124 as of Dec 31, 2025 (from $0).
• ·Produced and licensed content costs declined to $300,000 from $638,127.
• ·Common stock issued for services: 1,000,000 shares in 2025; stock option compensation $379,065.
• ·Net loss per common share: $(0.00) basic and diluted in 2025 vs $(0.02) in 2024.

30-03-2026

OneIM Acquisition Corp., a SPAC formed on September 5, 2025, reported total assets of $479,596 (all deferred offering costs) and total liabilities of $513,730 as of December 31, 2025, resulting in a shareholder's deficit of $34,134. The company recorded a net loss of $59,134 from formation and general administrative expenses for the period from inception through December 31, 2025, with no cash on hand or operating cash flows. No revenue or business combination has occurred yet, highlighting pre-IPO status with risks including potential foreign asset concentration post-combination.

• ·Inception date: September 5, 2025
• ·Class A ordinary shares authorized: 200,000,000; none issued
• ·Class B ordinary shares authorized: 20,000,000
• ·Basic and diluted net loss per Class B ordinary share: ($0.01)
• ·Net cash used in operating activities: $0 (non-cash adjustments)
• ·Cash at end of period: $0

30-03-2026

Galaxy Gaming, Inc. reported FY 2025 total revenue of $30,873,552, down 2.7% YoY from $31,737,466, with core revenues declining 10.4% to $19,156,855 due to a 66.3% drop in perpetual license sales, partially offset by 13.2% growth in digital revenues to $11,716,697. Despite the revenue contraction, the company achieved net income of $1,483,619, reversing a $2,627,110 loss in 2024, driven by a 43.5% increase in operating income to $8,179,610 from lower costs and expenses (-12.8%) and reduced interest expense; adjusted EBITDA rose slightly to $13,257,035 from $13,040,932. Cash and equivalents decreased to $4,306,683 from $18,118,043 following debt refinancing activities.

• ·Revenue by region: Americas $17,018,643 (down from $19,132,584), Europe/Middle East/Africa $13,854,909 (up from $12,604,882).
• ·Total assets decreased to $27,500,619 from $41,010,731; total liabilities $44,974,894 from $61,065,070.
• ·Stockholders’ deficit improved to $(17,474,275) from $(20,054,339).
• ·Net cash provided by operating activities $7,697,622 (up from $4,098,634).

30-03-2026

Unicycive Therapeutics reported a narrowed net loss of $26,555 thousand for the year ended December 31, 2025, improving 28% from $36,729 thousand in 2024, primarily due to a 54% reduction in research and development expenses to $9,121 thousand, though general and administrative expenses rose 69% to $20,396 thousand. Total operating expenses declined 8% to $29,517 thousand, but cash used in operating activities increased to $31,317 thousand from $28,575 thousand, with net cash increase dropping sharply to $3,056 thousand. Cash and equivalents rose to $29,198 thousand as of December 31, 2025, while total assets grew to $49,135 thousand and stockholders' equity to $30,197 thousand.

• ·Common stock shares outstanding increased to 22,114,245 as of Dec 31, 2025 from 11,384,236 as of Dec 31, 2024.
• ·Warrant liability decreased to $16,915 thousand as of Dec 31, 2025 from $18,936 thousand.
• ·No revenue recognized in either 2024 or 2025; company pre-commercial pending FDA approval for oxylanthanum carbonate.
• ·Series A-2 Prime preferred shares outstanding reduced to 2,265 as of Dec 31, 2025 from 6,150.21; Series B-2 to zero from 3,000.

30-03-2026

Neumora Therapeutics reported a narrowed net loss of $236.9M for the year ended December 31, 2025, compared to $243.8M in 2024, primarily due to lower operating expenses with R&D decreasing $24.9M (12.4% YoY) and G&A down $2.4M (3.9% YoY). However, cash used in operating activities worsened to $206.4M from $182.9M (12.8% increase in usage), total assets declined 40% to $191.0M from $317.0M, and stockholders' equity dropped 64% to $103.9M from $287.1M amid reduced marketable securities and increased long-term debt.

• ·EPS basic and diluted improved to $(1.45) from $(1.53).
• ·Interest income declined to $8.3M from $19.9M; new interest expense of $3.2M.
• ·Acquired in-process R&D expense of $5.0M in 2025 (none in 2024).
• ·Cash and cash equivalents increased to $182.5M from $142.1M; no short-term marketable securities at Dec 31 2025 vs $165.4M prior year.
• ·Long-term debt increased to $54.5M from $0.
• ·Stock-based compensation decreased to $29.9M from $40.0M.

30-03-2026

For the three months ended January 31, 2026, Helio Corp reported total revenue of $495,550, a sharp 65% YoY decline from $1,427,576, driven by drops in service fees (-42%), engineering fees (-91%), and materials (-92%). Operating expenses surged 129% YoY to $2,926,201, primarily from higher general and administrative costs, resulting in a net loss of $3,733,728 versus $919,142 last year. However, cash increased to $282,061 from $7,305 QoQ due to financing activities, and shareholders' deficit improved slightly to $(3,886,719).

• ·Common stock shares doubled to 23,182,425 from 11,371,966 due to issuances for services (4,262,000 shares), note conversions (7,398,459 shares), and with notes (150,000 shares).
• ·Derivative liability increased to $498,690 from $39,543 QoQ.
• ·Net cash used in operating activities improved to $(290,619) from $(501,760) YoY.
• ·Proceeds from financing: $100,000 notes payable, $559,762 convertible notes, $187,715 related party notes.

30-03-2026

SportsQuest, Inc. reported a narrowed net loss of $121,640 for the year ended December 31, 2025, improved 46.5% from $227,443 in 2024, driven by a 22.8% reduction in total operating expenses to $90,140, including declines in bank charges, administrative expenses, and consulting services. However, the company generated no revenue in either year, cash balances dwindled to $259 from $3,191 amid ongoing cash burn from operations, and total liabilities rose to $460,264 from $426,556. Stockholders' equity remained deeply negative at $(460,005), slightly worse than $(423,365) prior year.

• ·Convertible notes payable increased to $319,204 from $302,395; accrued interest payable to $141,060 from $124,161.
• ·Gain/(loss) from settlement/debt extinguishment improved to $(31,500) from $(110,682).
• ·Net cash provided by financing activities $101,809 in 2025 vs $217,702 in 2024.
• ·No cash flows from investing activities in either year.
• ·Net loss per share improved to $(0.00003) from $(0.00006).

30-03-2026

For the year ended December 31, 2025, CytoSorbents Corp reported product revenue of $37.1 million, up 4.1% from $35.6 million in 2024, with gross margins improving to 71.5% from 69.9% and R&D expenses decreasing significantly to $5.1 million from $7.6 million. Loss from operations narrowed 10.4% to $14.7 million from $16.5 million; however, SG&A expenses rose to $35.6 million from $33.7 million, and the company still posted a net loss of $8.2 million, though improved from $20.7 million prior year, aided by a $9.3 million foreign currency gain.

• ·Berlin office leases require $12,100 monthly base rent plus $3,000 operating expenses, initial term ends August 31, 2031.
• ·Restructuring expenses of $510 thousand in 2025.
• ·Interest expense increased to $2,612 thousand in 2025 from $1,399 thousand in 2024.
• ·Gain on foreign currency transactions of $9,321 thousand in 2025 vs loss of $4,225 thousand in 2024.

30-03-2026

PMGC Holdings Inc. reported flat revenue of 590,084 and gross profit of 185,314 for the year ended December 31, 2025, unchanged from 2024. However, total operating expenses nearly doubled to 7,067,262 from 3,663,566, driven by increases in office and administration (105%), professional fees (153%), and consulting fees (29%), while marketing and promotion declined 31%; this resulted in a widened net loss of 7,780,740 from 4,016,714. The company stated no intention to declare dividends, with returns dependent on stock appreciation, and highlighted risks in its acquisition-driven growth strategy.

• ·No intention to declare dividends on Common Stock in the foreseeable future.
• ·Other income (expense) worsened to $(867,820) from $(353,148).
• ·Weighted average shares outstanding increased from 947 to 20,352.

30-03-2026

The 10-K annual report for PSNH FUNDING LLC 3, filed on March 30, 2026, provides biographical details on its executive officers. Key officers include Jay S. Buth (56, Vice President, Controller and Chief Accounting Officer since 2018), John M. Moreira (65, President, CFO, Treasurer and Manager since May 2022), Matthew Fallon (51, Assistant Treasurer and Manager since October 2025), and Michelle A. Dreyer (54, Independent Manager since May 2018). These individuals bring expertise in accounting, finance, regulatory compliance, treasury operations, and investor relations from roles at Eversource, PSNH, and other entities.

• ·Jay S. Buth has served as Controller of Eversource and PSNH since April 2012 and is a Certified Public Accountant.
• ·John M. Moreira previously served as Senior Vice President-Finance and Regulatory from September 2018 to May 2022 and oversees capital structure, liquidity, financing, and regulatory compliance; he is a Certified Public Accountant.
• ·Matthew Fallon previously served as Director of Investor Relations for Eversource Energy Service Company (March 2024-September 2025) and at Pacific Gas & Electric, with 20 years of experience.
• ·Michelle A. Dreyer joined Corporation Service Company in 1999, serving as Manager of Independent Director Services since 2005 and Managing Director since 2019.

30-03-2026

Aura Biosciences reported a net loss of $106.2 million for the year ended December 31, 2025, widening 22% YoY from $86.9 million, driven by a 23% increase in R&D expenses to $90.3 million while G&A expenses remained nearly flat, decreasing slightly by 1% to $22.5 million. Total operating expenses rose 17% to $112.8 million, but the company raised $77.2 million through financing activities including a follow-on offering, leading to a net cash increase of $28.0 million and cash equivalents rising to $59.5 million from $31.7 million. Total assets declined to $169.4 million from $182.5 million, with stockholders' equity at $136.9 million.

• ·Stock-based compensation expense increased to $14.3 million in 2025 from $11.7 million.
• ·Marketable securities decreased to $84.7 million as of Dec 31 2025 from $119.4 million.
• ·Accumulated deficit grew to $(480.4) million from $(374.2) million.
• ·Follow-on offering net proceeds: $46.5 million common stock, $14.2 million pre-funded warrants, $9.3 million warrants.
• ·ATM facility issuance net: $6.1 million.

30-03-2026

Eikon Therapeutics reported a widened net loss of $324,248 thousand for the year ended December 31, 2025, up 33% from $243,814 thousand in 2024, driven by total operating expenses rising 30% to $338,945 thousand with R&D up 22% and G&A up 59%. While the company raised $352,053 thousand through financing activities including Series D preferred stock issuance netting $350,153 thousand, operating cash use increased 40% to $188,516 thousand and cash & equivalents fell to $104,901 thousand from $129,179 thousand. Total assets grew to $594,734 thousand supported by higher marketable securities of $231,074 thousand, though stockholders' deficit deepened to $879,034 thousand.

• ·Impairment of operating lease right-of-use assets: $10,275 thousand in 2025
• ·Impairment of property and equipment: $10,951 thousand in 2025
• ·Net loss per share basic and diluted: $(115.29) in 2025 vs $(96.76) in 2024
• ·Stock-based compensation expense: $18,036 thousand in 2025 (up from $12,429 thousand)
• ·Purchase of marketable securities: $444,102 thousand in 2025
• ·Proceeds from maturities of marketable securities: $309,500 thousand in 2025

30-03-2026

USA Rare Earth, Inc. generated first-year revenue of $1,643 thousand in 2025 (from $0 in 2024), primarily from Europe ($1,496 thousand) with a gross margin of 11.9%. However, operating expenses ballooned with SG&A up 370.0% to $43,135 thousand and total operating expenses to $59,698 thousand (from $15,585 thousand), compounded by a $244,488 thousand loss on fair value of financial instruments, resulting in a net loss of $298,524 thousand versus $16,392 thousand in 2024. Financing activities provided $531,715 thousand in cash, increasing cash and equivalents to $359,925 thousand and total assets to $694,999 thousand.

• ·Property, plant and equipment, net increased to $86,449 thousand as of December 31, 2025 from $26,529 thousand.
• ·Goodwill of $134,848 thousand and other intangible assets, net of $68,612 thousand recognized as of December 31, 2025.
• ·Accumulated deficit grew to $(387,360) thousand as of December 31, 2025 from $(72,872) thousand.
• ·Net cash used in operating activities increased to $(48,985) thousand in 2025 from $(12,991) thousand.
• ·Net cash used in investing activities was $(139,566) thousand in 2025.

30-03-2026

The 10-K annual report for STRATS(SM) Trust for Goldman Sachs Group Securities, Series 2006-2 (GJS), filed on March 30, 2026, includes a Regulation AB servicing criteria compliance table. It outlines general servicing considerations and cash collection/administration procedures, marking criteria as performed directly by the company (e.g., monitoring triggers, outsourcing oversight, payment deposits, wire disbursements, account maintenance), by vendors responsible to the company, or not applicable (e.g., back-up servicer, fidelity bond, advances, aggregation accuracy). No deficiencies or non-compliance issues are reported.

30-03-2026

Benchmark 2025-V19 Mortgage Trust filed its Form 10-K annual report for the fiscal year ended December 31, 2025, on March 30, 2026, including assessments of compliance with servicing criteria and servicer compliance statements from entities like Midland Loan Services and Citibank, N.A. Explanatory notes highlight that key mortgage loans—Empire Mall (6.8% of initial pool), 9911 Belward (4.1%), 1700 Pavillion (3.4%), and Central Arts Plaza (1.2%)—are parts of loan combinations serviced under separate PSAs such as WFCM 2025-5C7 and Benchmark 2025-V18. No material legal proceedings, significant obligors, or external credit enhancements are reported, with most traditional financial sections omitted as is standard for such trusts.

• ·No mortgage loan in the pool constitutes a significant obligor per Item 1101(k)(2) of Regulation AB.
• ·No external credit enhancement, derivative instruments, or other support for certificates.
• ·No unresolved staff comments, legal proceedings material to security holders, or cybersecurity disclosures required.

30-03-2026

FIRST KEYSTONE CORP reported net income of $6,152 thousand in 2025, recovering from a $13,203 thousand loss in 2024 primarily due to a 16.6% increase in net interest income to $37,651 thousand and a 33.0% decline in non-interest expense to $33,909 thousand after excluding a one-time $19,133 thousand goodwill impairment. Total assets grew 7.2% to $1,530,977 thousand, driven by 8.8% deposit growth to $1,137,437 thousand. However, non-performing assets surged 240% to $16,919 thousand (1.79% of total loans, up from 0.52%), with provision for credit losses rising to $4,700 thousand from $1,640 thousand.

• ·Net interest margin improved to 2.66% in 2025 from 2.40% in 2024.
• ·Individually evaluated loans to total loans increased to 1.80% at Dec 31, 2025 from 0.48% at Dec 31, 2024.
• ·Dividends per share remained flat at $1.12 for 2025.

30-03-2026

Chase Issuance Trust filed its 10-K for the fiscal year ended December 31, 2025, confirming that servicing participants JPMorgan Chase Bank and Computershare Trust Company, National Association, complied with applicable servicing criteria with no material instances of noncompliance. The filing discloses ongoing class action lawsuits, arbitrations, and mass arbitrations against JPMorgan Chase Bank regarding credit card practices and industry interchange fee antitrust claims, including a trial scheduled for April 2026, though the sponsor states these will not have a material adverse effect on receivables. It also notes the Illinois Interchange Fee Prohibition Act effective July 2026, which is being challenged in court.

• ·Merger of Chase Bank USA into JPMorgan Chase Bank effective May 18, 2019.
• ·Fifth Amended and Restated agreements dated December 16, 2024, including Transfer and Servicing Agreement, Indenture, and others, incorporated by reference.
• ·Over 90% of opt-out merchants in interchange fee litigation have settled.
• ·Servicer compliance statement covers period January 1, 2025 to December 31, 2025.

30-03-2026

Aktis Oncology reported total revenue of $6,497, a 337% YoY increase from $1,487 in 2024, entirely from collaboration revenue. However, operating expenses rose 52% to $81,181, primarily due to R&D expenses surging 65% to $67,451 amid higher spending on programs like [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519, resulting in loss from operations widening to $(74,684) from $(52,050) and net loss expanding to $(63,731) from $(43,980). Cash and cash equivalents remained nearly flat at $37,784 as of December 31, 2025, while marketable securities declined 27% to $189,003.

• ·Direct R&D expenses: [225Ac]Ac-AKY-1189 $11,443 (up from $5,988); [225Ac]Ac-AKY-2519 $7,311 (up from $385).
• ·Unallocated R&D: Employee-related $22,921 (up 63%); Facility/lab/depreciation $11,529 (up 14%).
• ·G&A details: Professional/consulting expenses $4,922 (down from $5,164); Facility/depreciation/other $1,132 (down from $1,276).
• ·Net cash investing activities $65,964 provided in 2025 (vs $(190,400) used in 2024).
• ·Total assets $264,885 as of Dec 31, 2025 (down from $326,181); Total liabilities $77,625 (down slightly from $80,575).

30-03-2026

Cleco Securitization I LLC filed its 10-K annual report on March 30, 2026, disclosing details on executive officers and employment history. William G. Fontenot, 63, has served as President and Chief Executive Officer of Cleco Corporate Holdings LLC since January 2018 and President and Manager of Cleco Securitization I LLC since March 2025. Samuel S. Kennedy, 41, was appointed Controller and Chief Accounting Officer since January 2026, with prior roles including Assistant Controller and positions at Vermont Gas Systems, Inc. and PricewaterhouseCoopers.

• ·Cleco Power LLC is a wholly owned subsidiary of Cleco Corporate Holdings LLC.
• ·Financial statements and schedules are not applicable per the filing.
• ·List of exhibits incorporated by reference.

30-03-2026

Cleco Securitization II LLC filed its 10-K annual report on March 30, 2026, primarily disclosing executive management details for William G. Fontenot (63, President and Manager since March 2025) and Samuel S. Kennedy (41, Controller and Chief Accounting Officer since January 2026). The filing indicates that financial statements and schedules are not applicable, with exhibits incorporated by reference. No quantitative financial performance data or period comparisons are provided.

• ·William G. Fontenot: President and CEO of Cleco Corporate Holdings LLC since January 2018; CEO of Cleco Power LLC since February 2019; President and Manager of Cleco Securitization I LLC since June 2022.
• ·Samuel S. Kennedy: Assistant Controller from May 2022 to December 2025; Controller at Vermont Gas Systems, Inc. from September 2021 to April 2022; Director at PricewaterhouseCoopers from July 2015 to September 2021.
• ·Cleco Power LLC is a wholly owned subsidiary of Cleco Corporate Holdings LLC.

30-03-2026

ARKO Petroleum Corp. reported total revenues of $5,581,264 thousand for FY 2025, down 12.3% YoY from $6,367,739 thousand amid declines in fuel revenues (-4.4% for third-party, significant drop in related party) and total fuel gallons sold (-5.9% to 2,005,810 thousand gallons). Net income fell 18.6% to $32,727 thousand while operating income decreased 8.7% to $83,931 thousand; however, Adjusted EBITDA improved 3.1% to $143,513 thousand supported by higher fuel margins (10.3 cents per gallon total, up from 9.9) and growth in certain segment contributions like proprietary cardlock.

• ·Net cash used in investing activities FY2025: $(22,185) thousand, up from $(9,440) thousand in FY2024.
• ·Ratio of Net Debt to Adjusted EBITDA as of Dec 31 2025: 3.7x.
• ·Net cash provided by operating activities declined to $79,558 thousand in FY2025 from $106,757 thousand in FY2024.

30-03-2026

MESA Royalty Trust reported royalty income of $601,840 for 2025, down 7.3% YoY from $649,164, driven by an 11.7% decline in San Juan Basin NM natural gas production to 172,715 Mcf and elimination of production in San Juan Basin CO (from 64,875 Mcf). However, distributable income increased 10.3% to $510,906 ($0.2742 per unit), benefiting from lower general and administrative expenses ($171,832 vs. $196,399) and no cash reserves withheld (vs. $72,000 prior year), despite slightly lower interest income.

• ·Hugoton net production volumes remained at 0 Mcf natural gas, 0 Bbls NGL, and 0 Bbls oil in both 2025 and 2024.
• ·Total assets increased to $3,286,282 as of Dec 31, 2025 from $3,187,975.
• ·Cash reserves withheld for Trust expenses: $0 in 2025 vs. $72,000 in 2024.
• ·Accumulated amortization of net overriding royalty interests: $41,284,741 (2025) vs. $41,240,185 (2024).